Joanne Holland
Hoofd Techniek/Wetenschap/O&O bij CONDUIT PHARMACEUTICALS INC.
Actieve functies van Joanne Holland
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CONDUIT PHARMACEUTICALS INC. | Hoofd Techniek/Wetenschap/O&O | 19-03-2024 | - |
Loopbaan van Joanne Holland
Eerdere bekende functies van Joanne Holland
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Nuformix Technologies Ltd.
 Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Directeur/Bestuurslid | - | 31-05-2021 |
| Hoofd Techniek/Wetenschap/O&O | - | 31-05-2021 | |
| NUFORMIX PLC | Directeur/Bestuurslid | 01-01-2008 | 31-05-2021 |
| Hoofd Techniek/Wetenschap/O&O | 01-01-2008 | 24-05-2021 | |
| Oprichter | 01-01-2008 | 31-05-2021 |
Opleiding van Joanne Holland
| University of Leeds | Doctorate Degree |
Statistieken
Internationaal
| Verenigd Koninkrijk | 4 |
| Verenigde Staten | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 2 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| NUFORMIX PLC | Health Technology |
| CONDUIT PHARMACEUTICALS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Nuformix Technologies Ltd.
Nuformix Technologies Ltd. Pharmaceuticals: MajorHealth Technology Nuformix Technologies Ltd. engages in investment in pharmaceutical products. Its activities include development and discovery of patented novel cocrystal forms of approved small molecules, creating an IP portfolio containing 14 granted patents covering cocrystal forms of five small molecule drugs. It offers the NXP001 and NXP002. The company was founded by Dr. David Joszef Tapolzcay and Dr. Daniel Gooding on October 23, 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Joanne Holland
- Ervaring
